Chronic Obstructive Pulmonary Disease Drugs Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis
Chronic obstructive pulmonary disease is a type of obstructive lung disease characterized by long-term breathing problems and low airflow. The primary symptoms include shortness of breath and cough with sputum production. Chronic obstructive pulmonary disease is a progressive disease, meaning it typically aggravates over time. The two different kinds of COPD are emphysema and chronic bronchitis. Chronic bronchitis is a productive cough present for at least three months each year for two years. The individuals with such a cough are at a greater risk of developing COPD. Emphysem is also used for the abnormal air or other gas within tissues. The most common cause is tobacco smoking, with a smaller number of cases due to air pollution and genetics. In the developing world, familiar sources of air pollution are wood combustion, and cooking fires. Moreover, long-term exposure to these risk factors causes an inflammatory reaction in the lungs, leading to narrowing of the small air passages and breakdown of lung tissue. COPD is diagnosed based on low airflow as measured by lung function tests.
MARKET DYNAMICS
The chronic obstructive pulmonary disease drug market has shown a significant evolution over the forecast period. The key driving factors include increased incidence and prevalence of COPD, technological advancements, and a growing aging population. As per the US Census Bureau's Statistics, as of 2021, the total number of people aged between 65 and older exceeded 50 million. According to the United Nations, during 2015-2031, the number of older persons aged 60 years or worldwide is projected to grow from 901 million to more than 1.4 billion. The significant factors that cause COPD are exposure to air pollution , cigarette smoke, rare genetic condition, chemical fumes or dust, among others. The Lancet Respiratory Medicine published an article in 2021, revealed that permanent lung tissue damage caused due to COPD begins even before the patient experiences any symptoms. Besides, technological advancements are anticipated to provide lucrative market opportunities. However, limitations of traditional treatments, such as late-onset of action and low efficacy, and stringent government regulations are likely to restrict the market growth.
MARKET SCOPE
The "Chronic Obstructive Pulmonary Disease Drugs Market Analysis to 2031" is a specialized and in-depth study of pharmaceuticals in the healthcare industry, focusing on the global market trend analysis. This report outlines the chronic obstructive pulmonary disease drugs market with detailed market segmentation by disease type, therapy, and end-user. The chronic obstructive pulmonary disease drug market is expected to witness high growth during the forecast period. The report focuses on the vital statistics on the market status of the leading players in the chronic obstructive pulmonary disease drugs market and offers key trends and opportunities.
MARKET SEGMENTATION
The market is segmented based on disease type, therapy, and end-user. Based on disease type, the market is categorized as emphysema and chronic bronchitis. Based on the therapy, the market is segmented as bronchodilators, steroids, anti-inflammatory drugs, and others. Based on the end-user, the market is segmented as hospitals, clinics, and others.
REGIONAL FRAMEWORK
The report lays out a detail outline of the industry, including both qualitative and quantitative information. The report gives a sketch and forecast of the chronic obstructive pulmonary disease drugs market based on various segments. It also consists of market size and forecast estimates from the year 2021 to2031 concerning five major regions: North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South & Central America. The market by each region is then subsegmented into respective countries and segments. The report consists of the analysis and forecast of eighteen countries globally and the recent trend and opportunities prevailing in the region.
The report analyzes factors affecting the chronic obstructive pulmonary disease drug market from both the demand and supply side. Furthermore, it evaluates market dynamics affecting the market during the forecast period, i.e., drivers, restraints, opportunities, and future trends. The report also comprises of precise PEST analysis for all five regions, namely; North America, Europe, APAC, MEA, and South & Central America, after evaluating political, economic, social, and technological factors affecting the chronic obstructive pulmonary disease drugs market in these regions.
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report lays out a detail outline of the industry, including both qualitative and quantitative information. The report gives a sketch and forecast of the chronic obstructive pulmonary disease drugs market based on various segments. It also consists of market size and forecast estimates from the year 2021 to2031 concerning five major regions: North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South & Central America. The market by each region is then subsegmented into respective countries and segments. The report consists of the analysis and forecast of eighteen countries globally and the recent trend and opportunities prevailing in the region.
The report analyzes factors affecting the chronic obstructive pulmonary disease drug market from both the demand and supply side. Furthermore, it evaluates market dynamics affecting the market during the forecast period, i.e., drivers, restraints, opportunities, and future trends. The report also comprises of precise PEST analysis for all five regions, namely; North America, Europe, APAC, MEA, and South & Central America, after evaluating political, economic, social, and technological factors affecting the chronic obstructive pulmonary disease drugs market in these regions.
MARKET PLAYERS
The report contains critical developments in the chronic obstructive pulmonary disease drugs market as organic and inorganic growth strategies. Various enterprises focus on organic growth strategies like product launches, product approvals, and others, such as patents and events. Inorganic growth strategies observed in the market were acquisitions and partnerships & collaborations. These activities have paved the way for the expansion of business and customer base of market players. The market players from the chronic obstructive pulmonary disease drugs market are anticipated to have profitable growth opportunities in the coming years with the rising demand for the chronic obstructive pulmonary disease drugs market globally. Given below is the list of few companies engaged in the chronic obstructive pulmonary disease drug market.
The report also consists of the profiles of key players in the chronic obstructive pulmonary disease drugs market, along with their SWOT analysis and market strategies. Additionally, the report elaborates on leading industry players with information on company profiles, components, and services provided, financial information of the last three years, critical development in the past five years.
- AstraZeneca
- Boehringer Ingelheim International GmbH
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd
- GlaxoSmithKline plc
- Abbott
- Astellas Pharma
- Circassia Pharmaceuticals plc
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and provides various customization options in the current study.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Chronic Obstructive Pulmonary Disease Drugs Market - By Disease Type
1.3.2 Chronic Obstructive Pulmonary Disease Drugs Market - By Therapy
1.3.3 Chronic Obstructive Pulmonary Disease Drugs Market - By End User
1.3.4 Chronic Obstructive Pulmonary Disease Drugs Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS - GLOBAL MARKET OVERVIEW
6.2. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE TYPE
7.1. OVERVIEW
7.2. DISEASE TYPE MARKET FORECASTS AND ANALYSIS
7.3. EMPHYSEMA
7.3.1. Overview
7.3.2. Emphysema Market Forecast and Analysis
7.4. CHRONIC BRONCHITIS
7.4.1. Overview
7.4.2. Chronic Bronchitis Market Forecast and Analysis
8. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - THERAPY
8.1. OVERVIEW
8.2. THERAPY MARKET FORECASTS AND ANALYSIS
8.3. BRONCHODILATORS
8.3.1. Overview
8.3.2. Bronchodilators Market Forecast and Analysis
8.4. STEROIDS
8.4.1. Overview
8.4.2. Steroids Market Forecast and Analysis
8.5. ANTI-INFLAMMATORY DRUGS
8.5.1. Overview
8.5.2. Anti-inflammatory Drugs Market Forecast and Analysis
8.6. OTHERS
8.6.1. Overview
8.6.2. Others Market Forecast and Analysis
9. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. CLINICS
9.4.1. Overview
9.4.2. Clinics Market Forecast and Analysis
9.5. OTHERS
9.5.1. Overview
9.5.2. Others Market Forecast and Analysis
10. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Chronic Obstructive Pulmonary Disease Drugs Market Overview
10.1.2 North America Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis
10.1.3 North America Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Disease Type
10.1.4 North America Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Therapy
10.1.5 North America Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By End User
10.1.6 North America Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Countries
10.1.6.1 United States Chronic Obstructive Pulmonary Disease Drugs Market
10.1.6.1.1 United States Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.1.6.1.2 United States Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.1.6.1.3 United States Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.1.6.2 Canada Chronic Obstructive Pulmonary Disease Drugs Market
10.1.6.2.1 Canada Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.1.6.2.2 Canada Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.1.6.2.3 Canada Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.1.6.3 Mexico Chronic Obstructive Pulmonary Disease Drugs Market
10.1.6.3.1 Mexico Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.1.6.3.2 Mexico Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.1.6.3.3 Mexico Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.2. EUROPE
10.2.1 Europe Chronic Obstructive Pulmonary Disease Drugs Market Overview
10.2.2 Europe Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis
10.2.3 Europe Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Disease Type
10.2.4 Europe Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Therapy
10.2.5 Europe Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By End User
10.2.6 Europe Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Chronic Obstructive Pulmonary Disease Drugs Market
10.2.6.1.1 Germany Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.2.6.1.2 Germany Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.2.6.1.3 Germany Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.2.6.2 France Chronic Obstructive Pulmonary Disease Drugs Market
10.2.6.2.1 France Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.2.6.2.2 France Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.2.6.2.3 France Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.2.6.3 Italy Chronic Obstructive Pulmonary Disease Drugs Market
10.2.6.3.1 Italy Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.2.6.3.2 Italy Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.2.6.3.3 Italy Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.2.6.4 Spain Chronic Obstructive Pulmonary Disease Drugs Market
10.2.6.4.1 Spain Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.2.6.4.2 Spain Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.2.6.4.3 Spain Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.2.6.5 United Kingdom Chronic Obstructive Pulmonary Disease Drugs Market
10.2.6.5.1 United Kingdom Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.2.6.5.2 United Kingdom Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.2.6.5.3 United Kingdom Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.2.6.6 Rest of Europe Chronic Obstructive Pulmonary Disease Drugs Market
10.2.6.6.1 Rest of Europe Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.2.6.6.2 Rest of Europe Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.2.6.6.3 Rest of Europe Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Market Overview
10.3.2 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis
10.3.3 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Disease Type
10.3.4 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Therapy
10.3.5 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Chronic Obstructive Pulmonary Disease Drugs Market
10.3.6.1.1 Australia Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.3.6.1.2 Australia Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.3.6.1.3 Australia Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.3.6.2 China Chronic Obstructive Pulmonary Disease Drugs Market
10.3.6.2.1 China Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.3.6.2.2 China Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.3.6.2.3 China Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.3.6.3 India Chronic Obstructive Pulmonary Disease Drugs Market
10.3.6.3.1 India Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.3.6.3.2 India Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.3.6.3.3 India Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.3.6.4 Japan Chronic Obstructive Pulmonary Disease Drugs Market
10.3.6.4.1 Japan Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.3.6.4.2 Japan Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.3.6.4.3 Japan Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.3.6.5 South Korea Chronic Obstructive Pulmonary Disease Drugs Market
10.3.6.5.1 South Korea Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.3.6.5.2 South Korea Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.3.6.5.3 South Korea Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.3.6.6 Rest of Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Market
10.3.6.6.1 Rest of Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.3.6.6.2 Rest of Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.3.6.6.3 Rest of Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market Overview
10.4.2 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis
10.4.3 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Disease Type
10.4.4 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Therapy
10.4.5 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Chronic Obstructive Pulmonary Disease Drugs Market
10.4.6.1.1 South Africa Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.4.6.1.2 South Africa Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.4.6.1.3 South Africa Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.4.6.2 Saudi Arabia Chronic Obstructive Pulmonary Disease Drugs Market
10.4.6.2.1 Saudi Arabia Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.4.6.2.2 Saudi Arabia Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.4.6.2.3 Saudi Arabia Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.4.6.3 U.A.E Chronic Obstructive Pulmonary Disease Drugs Market
10.4.6.3.1 U.A.E Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.4.6.3.2 U.A.E Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.4.6.3.3 U.A.E Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.4.6.4 Rest of Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market
10.4.6.4.1 Rest of Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.4.6.4.2 Rest of Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.4.6.4.3 Rest of Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Chronic Obstructive Pulmonary Disease Drugs Market Overview
10.5.2 South and Central America Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis
10.5.3 South and Central America Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Disease Type
10.5.4 South and Central America Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Therapy
10.5.5 South and Central America Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By End User
10.5.6 South and Central America Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Chronic Obstructive Pulmonary Disease Drugs Market
10.5.6.1.1 Brazil Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.5.6.1.2 Brazil Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.5.6.1.3 Brazil Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.5.6.2 Argentina Chronic Obstructive Pulmonary Disease Drugs Market
10.5.6.2.1 Argentina Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.5.6.2.2 Argentina Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.5.6.2.3 Argentina Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.5.6.3 Rest of South and Central America Chronic Obstructive Pulmonary Disease Drugs Market
10.5.6.3.1 Rest of South and Central America Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.5.6.3.2 Rest of South and Central America Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.5.6.3.3 Rest of South and Central America Chronic Obstructive Pulmonary Disease Drugs Market by End User
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS MARKET, KEY COMPANY PROFILES
12.1. ASTRAZENECA
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. MYLAN N.V.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. TEVA PHARMACEUTICAL INDUSTRIES LTD
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. GLAXOSMITHKLINE PLC
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. ABBOTT
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. ASTELLAS PHARMA
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. CIRCASSIA PHARMACEUTICALS PLC
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. PFIZER INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. F. HOFFMANN-LA ROCHE LTD
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. AstraZeneca
2. Boehringer Ingelheim International GmbH
3. Mylan N.V.
4. Teva Pharmaceutical Industries Ltd
5. GlaxoSmithKline plc
6. Abbott
7. Astellas Pharma
8. Circassia Pharmaceuticals plc
9. Pfizer Inc.
10. F. Hoffmann-La Roche Ltd
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For